OLEMA PHARMACEUTICALS INC. - COMMON STOCK

Olema Oncology Announces New Preclinical Data for OP-3136 Demonstrating Anti-Tumor Activity in Multiple Solid Tumor Models at AACR 2025

25 أبريل 2025 13:00:00 بحسب Nasdaq GlobeNewswire

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

02 أبريل 2025 16:30:00 بحسب Nasdaq GlobeNewswire

Olema Oncology to Present Preclinical Data for OP-3136, a Potent KAT6 Inhibitor, Demonstrating Anti-Tumor Activity in Multiple Solid Tumor Models at the 2025 AACR Annual Meeting

25 مارس 2025 16:31:00 بحسب Nasdaq GlobeNewswire

Olema Oncology Reports Fourth Quarter and Full Year 2024 Financial and Operating Results

18 مارس 2025 16:01:00 بحسب Nasdaq GlobeNewswire

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

04 مارس 2025 16:30:00 بحسب Nasdaq GlobeNewswire

Olema Oncology to Present at the TD Cowen 45th Annual Health Care Conference

19 فبراير 2025 16:30:00 بحسب Nasdaq GlobeNewswire

Olema Oncology Appoints Shawnte M. Mitchell, J.D. as Chief Legal Officer and Corporate Secretary

18 فبراير 2025 07:00:00 بحسب Nasdaq GlobeNewswire

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

04 فبراير 2025 16:30:00 بحسب Nasdaq GlobeNewswire

Olema Oncology to Participate in Upcoming Investor Conferences

03 فبراير 2025 16:30:00 بحسب Nasdaq GlobeNewswire

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

03 يناير 2025 16:30:00 بحسب Nasdaq GlobeNewswire

Olema Oncology to Present at 43rd Annual J.P. Morgan Healthcare Conference

02 يناير 2025 07:00:00 بحسب Nasdaq GlobeNewswire

Olema Oncology Presents Updated Clinical Results for Palazestrant in Combination with Ribociclib at the San Antonio Breast Cancer Symposium

10 ديسمبر 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Olema Oncology Announces FDA Clearance of Investigational New Drug Application for OP-3136, a Potent KAT6 Inhibitor

09 ديسمبر 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

03 ديسمبر 2024 16:30:00 بحسب Nasdaq GlobeNewswire

Olema Oncology Announces New Clinical Trial Collaboration and Supply Agreement with Novartis in Frontline Metastatic Breast Cancer as well as $250 Million Equity Private Placement

02 ديسمبر 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Olema Oncology to Present New Data Combining Palazestrant with Ribociclib at the San Antonio Breast Cancer Symposium

25 نوفمبر 2024 17:30:00 بحسب Nasdaq GlobeNewswire

Olema Oncology Reports Third Quarter 2024 Financial Results and Provides Corporate Update

12 نوفمبر 2024 16:01:00 بحسب Nasdaq GlobeNewswire

Olema Oncology to Participate in Upcoming Investor Conferences

06 نوفمبر 2024 07:01:11 بحسب Nasdaq GlobeNewswire

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

04 نوفمبر 2024 16:44:36 بحسب Nasdaq GlobeNewswire

Olema Oncology Presents Compelling New Preclinical Data Demonstrating Anti-Tumor Activity for OP-3136 with Enhanced Activity of Palazestrant Combinations at ENA 2024

23 أكتوبر 2024 07:00:00 بحسب Nasdaq GlobeNewswire